» Articles » PMID: 36787127

The Genetic Background Shapes the Susceptibility to Mitochondrial Dysfunction and NASH Progression

Abstract

Non-alcoholic steatohepatitis (NASH) is a global health concern without treatment. The challenge in finding effective therapies is due to the lack of good mouse models and the complexity of the disease, characterized by gene-environment interactions. We tested the susceptibility of seven mouse strains to develop NASH. The severity of the clinical phenotypes observed varied widely across strains. PWK/PhJ mice were the most prone to develop hepatic inflammation and the only strain to progress to NASH with extensive fibrosis, while CAST/EiJ mice were completely resistant. Levels of mitochondrial transcripts and proteins as well as mitochondrial function were robustly reduced specifically in the liver of PWK/PhJ mice, suggesting a central role of mitochondrial dysfunction in NASH progression. Importantly, the NASH gene expression profile of PWK/PhJ mice had the highest overlap with the human NASH signature. Our study exposes the limitations of using a single mouse genetic background in metabolic studies and describes a novel NASH mouse model with features of the human NASH.

Citing Articles

Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.

Geng W, Liao W, Cao X, Yang Y Biomedicines. 2025; 13(2).

PMID: 40002806 PMC: 11853636. DOI: 10.3390/biomedicines13020393.


Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.

Di X, Li Y, Wei J, Li T, Liao B Adv Sci (Weinh). 2024; 12(3):e2410416.

PMID: 39665319 PMC: 11744640. DOI: 10.1002/advs.202410416.


Ileal microbial microbiome and its secondary bile acids modulate susceptibility to nonalcoholic steatohepatitis in dairy goats.

Wang Y, Chen X, Huws S, Xu G, Li J, Ren J Microbiome. 2024; 12(1):247.

PMID: 39578870 PMC: 11585128. DOI: 10.1186/s40168-024-01964-0.


miR-21: A therapeutic target for delaying severe liver disease and hepatocellular carcinoma in high-fat-diet-fed mice.

Jagtap U, Quan A, Ono Y, Lee J, Shen K, Manakov S bioRxiv. 2024; .

PMID: 39386656 PMC: 11463666. DOI: 10.1101/2024.09.19.613915.


Unlocking metabolic insights with mouse genetic diversity.

Masson S, Cutler H, James D EMBO J. 2024; 43(21):4814-4821.

PMID: 39284908 PMC: 11535531. DOI: 10.1038/s44318-024-00221-2.


References
1.
Hubscher S . Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006; 49(5):450-65. DOI: 10.1111/j.1365-2559.2006.02416.x. View

2.
Goeminne L, Gevaert K, Clement L . Experimental design and data-analysis in label-free quantitative LC/MS proteomics: A tutorial with MSqRob. J Proteomics. 2017; 171:23-36. DOI: 10.1016/j.jprot.2017.04.004. View

3.
Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N . Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009; 51(5):918-24. DOI: 10.1016/j.jhep.2009.05.033. View

4.
Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M . Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. 2020; 12(572). DOI: 10.1126/scitranslmed.aba4448. View

5.
Ganeshan K, Chawla A . Warming the mouse to model human diseases. Nat Rev Endocrinol. 2017; 13(8):458-465. PMC: 5777302. DOI: 10.1038/nrendo.2017.48. View